Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating FDA trial updates, product revenue splits, and manufacturing risk factors inside Vericel’s dense biotech disclosures can feel overwhelming. Each 10-K explains cell-expansion costs, while sudden 8-Ks reveal trial results that move the stock overnight. If you have ever typed “Vericel SEC filings explained simply” or searched for “Vericel insider trading Form 4 transactions,” you already know the challenge.
Stock Titan solves it. Our AI reads every Vericel annual report 10-K, quarterly earnings report 10-Q filing, and real-time Form 4 insider transactions, then distills the numbers and legal language into plain English. Need to understand Vericel proxy statement executive compensation or track a surprise shipment issue flagged in a Vericel 8-K material events explained section? One click delivers an annotated summary, key metrics, and trend graphics. Subscribers receive alerts the moment a Vericel Form 4 insider transactions real-time filing hits EDGAR, helping you gauge executive confidence before the market reacts.
All filings appear in a single dashboard—historical and current—so you can:
- Compare cartilage-implant sales across quarters without scrolling 200 pages
- Monitor Vericel executive stock transactions Form 4 alongside price charts
- Export AI-driven ratios that spotlight R&D spending swings
Vericel (VCEL) delivered solid top-line growth in Q2-25 but remains loss-making year-to-date. Revenue rose 20% YoY to $63.2 m, driven mainly by MACI implants (+21% to $53.5 m) and the ongoing launch of NexoBrid (+52% to $1.2 m). Epicel contributed $8.6 m (+11%). Gross margin expanded to 74% (vs. 69%) as the largely fixed Cambridge manufacturing base leveraged higher volumes.
Operating expenses climbed 14% to $48.6 m, led by SG&A (+19% to $41.9 m) reflecting salesforce expansion, MACI Arthro marketing and Burlington facility depreciation. As a result, Q2 operating loss narrowed to $2.0 m (from $6.0 m) and net loss to $0.6 m, or $(0.01) per share. For 1H-25, revenue increased 11% to $115.8 m but net loss widened to $11.8 m due to higher costs.
Balance sheet remains strong: cash & equivalents $80.5 m, investments $83.7 m, no revolver borrowings, giving ~ $164 m liquidity. Operating cash flow was $14.8 m (vs. $25.7 m prior-year) after $22.3 m capex tied to the new Burlington manufacturing site, which will become the primary MACI/Epicel plant once validated.
Strategic highlights: FDA approvals in 2024 expanded MACI to arthroscopic delivery and NexoBrid to pediatric burns; management sees both as growth catalysts. Management projects liquidity is sufficient for at least 12 months.
FAQ
What is the current stock price of Vericel (VCEL)?
What is the market cap of Vericel (VCEL)?
What is the primary focus of Vericel Corporation?
How does Vericel generate its therapies?
What are the main products offered by Vericel?
How does Vericel differentiate itself in the regenerative medicine industry?
What are the benefits of using autologous cellular therapies?
How does Vericel maintain quality and regulatory compliance?
What role does research and development play at Vericel?
How is Vericel positioned within its competitive landscape?
